Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Livmoniplimab
DRUG: Budigalimab
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Gemcitabine

Sponsor

AbbVie